Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.

By R. Roy, Jiang Yang, M. Moses. Journal of Clinical Oncology, 2009

844 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/979a42de349eff5d02effa342569229a1cc1736e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Rakesh K. Jain
2. Triantafyllos Stylianopoulos
3. Dai Fukumura
4. John D. Martin
5. Vikash P Chauhan
6. N. Ferrara
7. Peter Carmeliet
8. J. Joyce

In Molecular Biology

1. Rakesh K. Jain
2. Triantafyllos Stylianopoulos
3. Dai Fukumura
4. John D. Martin
5. Vikash P Chauhan
6. J. Joyce
7. Peter Carmeliet
8. N. Ferrara

In Oncology

1. Rakesh K. Jain
2. Triantafyllos Stylianopoulos
3. Dai Fukumura
4. John D. Martin
5. Vikash P Chauhan
6. J. Joyce

Citations in the corpus

• Matrix MetalloProteinases (MMPs) andTissue Inhibitors of MetalloProteinases (TIMPs): positive and negative regulators intumor cell adhesion (2010, neutral): “In the current era of cancer genomics and proteomics, numerous studies have shown positive correlation between elevated MMP levels within the tumor stroma and tumor cells invasion or metastasis[15].”
• Multistage nanoparticle delivery system for deep penetration into tumor tissue (2011, background): “For example, high levels of tumorspecific urinary MMPs measured noninvasively in an individual can be indicative of high levels of the MMPs in plasma and tumor tissues (42).”